Blue Arrow Capital Management’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Blue Arrow Capital Management’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-2,000	Closed	-$121K	–	238
2014 Q4	$121K	Buy	+2,000	New	+$100K	0.01%	179
2014 Q2	–	Sell	-3,230	Closed	-$210K	–	206
2014 Q1	$210K	Buy	+3,230	New	+$218K	0.03%	104

Other funds holding OREX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Blue Arrow Capital Management's OREX Position: Q1 2015 in Review

Blue Arrow Capital Management sold out of Orexigen Therapeutics, Inc. (OREX) in Q1 2015, closing a stake of 2,000 shares — an estimated $121K sold.

Blue Arrow Capital Management first reported a position in OREX in Q1 2014 and held it in 2 quarters. The position peaked at $210K in Q1 2014. 160 funds tracked by Wall St. Rank hold OREX as of Q1 2015.

Blue Arrow Capital Management reported no remaining Orexigen Therapeutics, Inc. position as of Q1 2015 after selling out during the quarter.
Blue Arrow Capital Management sold 2,000 Orexigen Therapeutics, Inc. shares in Q1 2015, an estimated $121K.
Blue Arrow Capital Management first reported a position in Orexigen Therapeutics, Inc. in Q1 2014 and held it in 2 quarters.
Blue Arrow Capital Management's Orexigen Therapeutics, Inc. position peaked at $210K in Q1 2014.
160 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q1 2015.

Based on Blue Arrow Capital Management's 13F filing for Q1 2015, filed 15 May 2015.